NEW YORK (GenomeWeb News) – Affymetrix today said that it has expanded its license agreement with Siemens Healthcare Diagnostics for its branched DNA (bDNA) technology.

The Santa Clara, Calif.-based firm now has exclusive rights to develop and sell in situ QuantiGene ViewRNA products in the in vitro diagnostic market. The products are currently for research-use only. The license also provides Affy exclusive rights to alkaline phosphatase conjugated oligonucleotides and the use of them in bDNA methods for in situ detection using Fast Red substrates.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.